Literature DB >> 20547305

The changing pattern of epidemiology in hepatocellular carcinoma.

Helena Nordenstedt1, Donna L White, Hashem B El-Serag.   

Abstract

Primary liver cancer (PLC) represents approximately 4% of all new cancer cases diagnosed worldwide. The purpose of this review is to describe some of the latest international patterns in PLC incidence and mortality, as well as to give an overview of the main etiological factors. We used two databases, GLOBOCAN 2002 and the World Health Organization (WHO) mortality database to analyze the incidence and mortality rates for PLC in several regions around the world. The highest age adjusted incidence rates (>20 per 100,000) were reported from countries in Southeast Asia and sub-Saharan Africa that are endemic for HBV infection. Countries in Southern Europe have medium-high incidence rates, while low-incidence areas (<5 per 100,000) include South and Central America, and the rest of Europe. Cirrhosis is present in about 80-90% of HCC patients and is thereby the largest single risk factor. Main risk factors include HBV, HCV, aflatoxin and possibly obesity and diabetes. Together HBV and HCV account for 80-90% of all HCC worldwide. HBV continues to be the major HCC risk factor worldwide, although its importance will most likely decrease during the coming decades due to the widespread use of the HBV vaccine in the newborns. HCV has been the dominant viral cause in HCC in North America, some Western countries and Japan. Obesity and diabetes are increasing at a fast pace throughout the world, and if they are proven to be HCC risk factors, they would account for more HCC cases in the future. Copyright 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20547305      PMCID: PMC3392755          DOI: 10.1016/S1590-8658(10)60507-5

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  49 in total

1.  HBV + HCV = HCC?

Authors:  M E Cramp
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

2.  Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.

Authors:  Hashem B El-Serag; Abby B Siegel; Jessica A Davila; Yasser H Shaib; Mikele Cayton-Woody; Russell McBride; Katherine A McGlynn
Journal:  J Hepatol       Date:  2005-11-02       Impact factor: 25.083

Review 3.  Epidemiology of hepatocellular carcinoma.

Authors:  F Xavier Bosch; Josepa Ribes; Ramon Cléries; Mireia Díaz
Journal:  Clin Liver Dis       Date:  2005-05       Impact factor: 6.126

4.  Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma.

Authors:  Yu-jing Zhang; Yu Chen; Habibul Ahsan; Ruth M Lunn; Shu-Yuan Chen; Po-huang Lee; Chien-Jen Chen; Regina M Santella
Journal:  Cancer Lett       Date:  2005-04-28       Impact factor: 8.679

5.  High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors.

Authors:  P Fasani; A Sangiovanni; C De Fazio; M Borzio; S Bruno; G Ronchi; E Del Ninno; M Colombo
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

6.  Natural history of untreated nonsurgical hepatocellular carcinoma.

Authors:  Yuk Pang Yeung; Chung Mau Lo; Chi Leung Liu; Benjamin C Wong; Sheung Tat Fan; John Wong
Journal:  Am J Gastroenterol       Date:  2005-09       Impact factor: 10.864

Review 7.  Global epidemiology of hepatitis C virus infection.

Authors:  Colin W Shepard; Lyn Finelli; Miriam J Alter
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

8.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

9.  Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan.

Authors:  Taichi Shimazu; Yoshitaka Tsubono; Shinichi Kuriyama; Kaori Ohmori; Yayoi Koizumi; Yoshikazu Nishino; Daisuke Shibuya; Ichiro Tsuji
Journal:  Int J Cancer       Date:  2005-08-10       Impact factor: 7.396

Review 10.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

Authors:  Hashem B El-Serag; Howard Hampel; Fariba Javadi
Journal:  Clin Gastroenterol Hepatol       Date:  2006-03       Impact factor: 11.382

View more
  205 in total

1.  Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence.

Authors:  Marco Vivarelli; Andrea Risaliti
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

2.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

3.  Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations.

Authors:  Nimzing G Ladep; Shahid A Khan; Mary Me Crossey; Andrew V Thillainayagam; Simon D Taylor-Robinson; Mireille B Toledano
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

Review 4.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

5.  Sperm-associated antigen 9 is upregulated in hepatocellular carcinoma tissue and enhances QGY cell proliferation and invasion in vitro.

Authors:  Biqiong Ren; Guoying Zou; Junyu He; Yiran Huang; Guoan Ma; Guofeng Xu; Yong Li; Ping Yu
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

6.  Overexpression of SPAG9 correlates with poor prognosis and tumor progression in hepatocellular carcinoma.

Authors:  Chengyao Xie; Lin Fu; Nan Liu; Qingchang Li
Journal:  Tumour Biol       Date:  2014-05-08

7.  Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes.

Authors:  Erikka Loftfield; Neal D Freedman; Gabriel Y Lai; Stephanie J Weinstein; Katherine A McGlynn; Philip R Taylor; Satu Männistö; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Cancer Prev Res (Phila)       Date:  2016-08-29

8.  Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment.

Authors:  Pi-Yi Chang; Chun-Chieh Huang; Chao-Hung Hung; Chih-Yung Yu; Ding-Kwo Wu; Jen-I Hwang; Po-Chin Liang; Reng-Hong Wu; Wei-Lun Tsai; Yih-Jyh Lin; Yi-Sheng Liu; Huei-Lung Liang; Rheun-Chuan Lee; Chien-Hung Chen
Journal:  Liver Cancer       Date:  2018-03-29       Impact factor: 11.740

9.  Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients.

Authors:  Gia L Tyson; Peter A Richardson; Donna L White; Jill Kuzniarek; David J Ramsey; Shahriar Tavakoli-Tabasi; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2013-07       Impact factor: 3.062

Review 10.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.